BioNTech, Pfizer ask U.S. court for clearance over patent dispute with CureVac




  • In Health
  • 2022-07-26 12:18:19Z
  • By Reuters
 

By Ludwig Burger

FRANKFURT (Reuters) -COVID-19 vaccine maker BioNTech said on Tuesday that it and partner Pfizer have filed a complaint with the U.S. District Court in Massachusetts, seeking a judgment that they did not infringe U.S. patents held by rival CureVac.

CureVac earlier this month filed a patent lawsuit in Germany against BioNTech over its use of mRNA technology and did not rule out further legal action against BioNTech's partner Pfizer or rival mRNA vaccine maker Moderna.

BioNTech said that CureVac's U.S. patents, which BioNTech claims in its filing not to be in violation of, were equivalent to German patents invoked by CureVac in the German court case.

CureVac said in a statement it was aware of BioNTech's legal action but had not yet been formally served.

"We will review the matter legally in detail and represent our position accordingly," it added.

(Reporting by Ludwig Burger, editing by Kirsti Knolle)

COMMENTS

More Related News

Ohio State files rare legal appeal to maneuver Strauss survivors in court
Ohio State files rare legal appeal to maneuver Strauss survivors in court
  • US
  • 2022-09-28 10:12:45Z

Ohio State filed an en banc review in an attempt to reverse the Sixth U.S. Circuit Court of Appeals decision related to former doctor Richard Strauss.

Sanford man pleads guilty to setting apartment building on fire
Sanford man pleads guilty to setting apartment building on fire
  • US
  • 2022-09-27 20:25:16Z

Thomas McGinn, 49, could face up to 20 years in prison.

Pfizer-BioNTech asks FDA to authorize new omicron-targeting COVID booster for children 5 to 11
Pfizer-BioNTech asks FDA to authorize new omicron-targeting COVID booster for children 5 to 11

Pfizer-BioNTech submitted an application for the FDA to authorize its BA.4/BA.5 bivalent COVID-19 vaccine for kids 5 to 11 at a 10-microgram dose.

Pfizer seeks to expand omicron booster to 5- to 11-year-olds
Pfizer seeks to expand omicron booster to 5- to 11-year-olds

Pfizer asked U.S. regulators Monday to expand use of its updated COVID-19 booster shot to children ages 5 to 11. If the Food and Drug Administration agrees, they would start getting a kid-sized dose of the new omicron-targeted formula when it was time for their booster. FDA vaccine chief Dr. Peter Marks said last week he expected a decision on boosters for that age group soon.

Leave a Comment

Your email address will not be published. Required fields are marked with *

Cancel reply

Comments

  • 해외문자
    (2022-08-13 04:00:14Z)

    I read your post with great interest. I think it's great how you can think that. I'll try to stop by often.

    REPLY

Top News: Health